tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Reich K et al. | Topical tacrolimus for pyoderma gangrenosum. | 1998 | Br. J. Dermatol. | pmid:9892935 |
| Aoyama H et al. | Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. | 1995 | Br. J. Dermatol. | pmid:8547017 |
| Kyllönen H et al. | Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. | 2004 | Br. J. Dermatol. | pmid:15214906 |
| Meingassner JG et al. | Pimecrolimus does not affect Langerhans cells in murine epidermis. | 2003 | Br. J. Dermatol. | pmid:14616380 |
| Wilsmann-Theis D et al. | Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. | 2004 | Br. J. Dermatol. | pmid:15214910 |
| Lerbaek A and Agner T | Facial eruption of molluscum contagiosum during topical treatment of atopic dermatitis with tacrolimus. | 2004 | Br. J. Dermatol. | pmid:15214914 |
| Edmonds EV et al. | Nodular prurigo responding to topical tacrolimus. | 2004 | Br. J. Dermatol. | pmid:15214918 |
| Calza AM and Lübbe J | Tacrolimus ointment-associated alcohol intolerance in infants receiving ethanol-containing medication. | 2005 | Br. J. Dermatol. | pmid:15787832 |
| Rigopoulos D et al. | Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. | 2004 | Br. J. Dermatol. | pmid:15541087 |
| Clayton TH and Harrison PV | Successful treatment of chronic ulcerated necrobiosis lipoidica with 0.1% topical tacrolimus ointment. | 2005 | Br. J. Dermatol. | pmid:15787840 |
| RodrÃguez GarcÃa F et al. | Generalized pustular psoriasis successfully treated with topical tacrolimus. | 2005 | Br. J. Dermatol. | pmid:15787845 |
| Remitz A et al. | Tacrolimus ointment improves psoriasis in a microplaque assay. | 1999 | Br. J. Dermatol. | pmid:10417522 |
| Danby SG et al. | The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. | 2014 | Br. J. Dermatol. | pmid:24328907 |
| Weidinger S et al. | A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. | 2017 | Br. J. Dermatol. | pmid:28868633 |
| Charman C | A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment. | 2017 | Br. J. Dermatol. | pmid:28858382 |
| Vente C et al. | Erosive mucosal lichen planus: response to topical treatment with tacrolimus. | 1999 | Br. J. Dermatol. | pmid:10233234 |
| Lyon CC et al. | Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. | 1999 | Br. J. Dermatol. | pmid:10233300 |
| Simon D et al. | Successful treatment of pityriasis lichenoides with topical tacrolimus. | 2004 | Br. J. Dermatol. | pmid:15149526 |
| Jain S and Stephens CJ | Successful treatment of disseminated granuloma annulare with topical tacrolimus. | 2004 | Br. J. Dermatol. | pmid:15149532 |
| Koguchi-Yoshioka H et al. | Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules. | 2017 | Br. J. Dermatol. | pmid:28346662 |
| Ghislain PD et al. | Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. | 2004 | Br. J. Dermatol. | pmid:15149540 |
| Katoh N et al. | Cutaneous sarcoidosis successfully treated with topical tacrolimus. | 2002 | Br. J. Dermatol. | pmid:12100200 |
| Griffiths CE | Ascomycin: an advance in the management of atopic dermatitis. | 2001 | Br. J. Dermatol. | pmid:11298524 |
| Harper J et al. | First experience of topical SDZ ASM 981 in children with atopic dermatitis. | 2001 | Br. J. Dermatol. | pmid:11298537 |
| Luger T et al. | SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. | 2001 | Br. J. Dermatol. | pmid:11298538 |
| Fricain JC et al. | Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. | 2007 | Br. J. Dermatol. | pmid:17300261 |
| Vissers WH et al. | Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression. | 2008 | Br. J. Dermatol. | pmid:18284400 |
| Reitamo S et al. | 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. | 2004 | Br. J. Dermatol. | pmid:15030341 |
| Ormerod AD | Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? | 2005 | Br. J. Dermatol. | pmid:16181449 |
| Lan CC et al. | FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. | 2005 | Br. J. Dermatol. | pmid:16181452 |
| Vukmanovic-Stejic M et al. | Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:16181456 |
| Martin-Munoz MF et al. | Topical treatment tacrolimus and food allergy. | 2005 | Br. J. Dermatol. | pmid:16181473 |
| Erdogan M et al. | Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model. | 2002 | Br. J. Dermatol. | pmid:12072063 |
| Reitamo S et al. | A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. | 2008 | Br. J. Dermatol. | pmid:18637898 |
| Barbier N et al. | Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. | 2004 | Br. J. Dermatol. | pmid:14746622 |
| Rubegni P et al. | A case of reticular erythematous mucinosis treated with topical tacrolimus. | 2004 | Br. J. Dermatol. | pmid:14746650 |
| Abe R et al. | Severe refractory chronic actinic dermatitis successfully treated with tacrolimus ointment. | 2002 | Br. J. Dermatol. | pmid:12452891 |
| Bäumer W et al. | Cilomilast, tacrolimus and rapamycin modulate dendritic cell function in the elicitation phase of allergic contact dermatitis. | 2005 | Br. J. Dermatol. | pmid:16029339 |
| Wollenberg A et al. | Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. | 2008 | Br. J. Dermatol. | pmid:18782316 |
| Doss N et al. | Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial. | 2009 | Br. J. Dermatol. | pmid:19416227 |
| Thaçi D et al. | Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. | 2008 | Br. J. Dermatol. | pmid:18782319 |
| Leung DY et al. | Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. | 2009 | Br. J. Dermatol. | pmid:19416245 |
| Hickey JR et al. | Does topical tacrolimus induce lentigines in children with atopic dermatitis? A report of three cases. | 2005 | Br. J. Dermatol. | pmid:15656817 |
| Mancuso G and Berdondini RM | Localized scleroderma: response to occlusive treatment with tacrolimus ointment. | 2005 | Br. J. Dermatol. | pmid:15656828 |
| Langeland T and Engh V | Topical use of tacrolimus and squamous cell carcinoma on the penis. | 2005 | Br. J. Dermatol. | pmid:15656830 |
| Kreuter A et al. | Pimecrolimus 1% cream for perianal atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:15656832 |
| Brouard MC et al. | Erosive pustular dermatosis of the leg: report of three cases. | 2002 | Br. J. Dermatol. | pmid:12366427 |
| Queille-Roussel C et al. | The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. | 2001 | Br. J. Dermatol. | pmid:11260007 |
| Rao A and Bunker C | Efficacy and safety of tacrolimus ointment 0.1% vs. betamethasone 17-valerate 0.1% in the treatment of chronic paronychia: an unblinded randomized study. | 2010 | Br. J. Dermatol. | pmid:20353455 |
| Oji V et al. | Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. | 2005 | Br. J. Dermatol. | pmid:16225628 |
| Connolly M and Kennedy C | Exfoliative cheilitis successfully treated with topical tacrolimus. | 2004 | Br. J. Dermatol. | pmid:15270904 |
| Healy E et al. | Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. | 2011 | Br. J. Dermatol. | pmid:21083544 |
| Clayton TH et al. | Topical tacrolimus for facial psoriasis. | 2003 | Br. J. Dermatol. | pmid:12932257 |
| Tzung TY and Wu JC | Topical calcineurin inhibitors in treating Jessner's lymphocytic infiltration of the skin: report of a case. | 2005 | Br. J. Dermatol. | pmid:15727667 |
| Poole CD et al. | Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study. | 2009 | Br. J. Dermatol. | pmid:19754867 |
| Chu CY | The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. | 2005 | Br. J. Dermatol. | pmid:15727676 |
| Park CW et al. | Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:15948978 |
| Gottlieb AB et al. | Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. | 2005 | Br. J. Dermatol. | pmid:15948985 |
| Bhol KC and Schechter PJ | Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. | 2005 | Br. J. Dermatol. | pmid:15948987 |
| Reitamo S et al. | A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. | 2005 | Br. J. Dermatol. | pmid:15948994 |
| Feldmann KA et al. | Is topical tacrolimus effective in alopecia areata universalis? | 2002 | Br. J. Dermatol. | pmid:12410729 |
| Sigurgeirsson B and Luger T | A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - author response. | 2017 | Br. J. Dermatol. | pmid:28940181 |
| Rigopoulos D et al. | Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. | 2006 | Br. J. Dermatol. | pmid:16792767 |
| Chohan R et al. | Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. | 2003 | Br. J. Haematol. | pmid:14510951 |
| Mehta RS et al. | Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. | 2016 | Br. J. Haematol. | pmid:26947769 |
| Pulsipher MA et al. | A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). | 2009 | Br. J. Haematol. | pmid:19744131 |
| Murata M et al. | A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation. | 1999 | Br. J. Haematol. | pmid:10354150 |
| Armand P et al. | The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. | 2016 | Br. J. Haematol. | pmid:26729448 |
| Wong R et al. | Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. | 2003 | Br. J. Haematol. | pmid:12823354 |
| Feliu J et al. | Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies. | 2014 | Br. J. Haematol. | pmid:24962133 |
| Couriel DR et al. | Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. | 2005 | Br. J. Haematol. | pmid:16042691 |
| Mollee P et al. | Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. | 2001 | Br. J. Haematol. | pmid:11328304 |
| Kida A et al. | Calcineurin-inhibitor pain syndrome following haematopoietic stem cell transplantation. | 2004 | Br. J. Haematol. | pmid:15257699 |
| Boulad F et al. | Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. | 2000 | Br. J. Haematol. | pmid:11167755 |
| Dusting GJ et al. | Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. | 1999 | Br. J. Pharmacol. | pmid:10510443 |
| Quintá HR and Galigniana MD | The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. | 2012 | Br. J. Pharmacol. | pmid:22091865 |
| Klettner A and Herdegen T | The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response. | 2003 | Br. J. Pharmacol. | pmid:12642403 |
| Magari K et al. | Calcineurin inhibitors exert rapid reduction of inflammatory pain in rat adjuvant-induced arthritis. | 2003 | Br. J. Pharmacol. | pmid:12839866 |
| Simon N et al. | Tacrolimus and sirolimus decrease oxidative phosphorylation of isolated rat kidney mitochondria. | 2003 | Br. J. Pharmacol. | pmid:12540528 |
| Øzbay LA et al. | Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. | 2011 | Br. J. Pharmacol. | pmid:20825407 |
| Bader A et al. | Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. | 2000 | Br. J. Pharmacol. | pmid:10694240 |
| Squadrito F et al. | Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. | 1999 | Br. J. Pharmacol. | pmid:10385251 |
| Price RD et al. | FK506 potentiates NGF-induced neurite outgrowth via the Ras/Raf/MAP kinase pathway. | 2003 | Br. J. Pharmacol. | pmid:14559856 |
| Hortelano S et al. | Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. | 1999 | Br. J. Pharmacol. | pmid:10205001 |
| Harrison S et al. | Stimulation of airway sensory nerves by cyclosporin A and FK506 in guinea-pig isolated bronchus. | 1998 | Br. J. Pharmacol. | pmid:9884067 |
| Eum SY et al. | Inhibition by the immunosuppressive agent FK-506 of antigen-induced airways eosinophilia and bronchial hyperreactivity in mice. | 1997 | Br. J. Pharmacol. | pmid:9117088 |
| Yasutsune T et al. | Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery. | 1999 | Br. J. Pharmacol. | pmid:10188984 |
| Deters M et al. | Sirolimus/cyclosporine/tacrolimus interactions on bile flow and biliary excretion of immunosuppressants in a subchronic bile fistula rat model. | 2002 | Br. J. Pharmacol. | pmid:12055139 |
| MacMillan D and McCarron JG | Regulation by FK506 and rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular smooth muscle: the role of FK506 binding proteins and mTOR. | 2009 | Br. J. Pharmacol. | pmid:19785652 |
| Waschulewski IH et al. | Effects of the immunosuppressants cyclosporin A and FK 506 on exocytosis in the rat exocrine pancreas in vitro. | 1993 | Br. J. Pharmacol. | pmid:7683567 |
| Weidelt T and Isenberg G | Augmentation of SR Ca(2+) release by rapamycin and FK506 causes K(+)-channel activation and membrane hyperpolarization in bladder smooth muscle. | 2000 | Br. J. Pharmacol. | pmid:10742283 |
| Gardiner SM et al. | Regional haemodynamic effects of cyclosporine A, tacrolimus and sirolimus in conscious rats. | 2004 | Br. J. Pharmacol. | pmid:14744807 |
| Pahl A et al. | Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy. | 2002 | Br. J. Pharmacol. | pmid:11959794 |
| Seidel ER and Ragan VL | Inhibition by rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC-6 cells in culture. | 1997 | Br. J. Pharmacol. | pmid:9051292 |
| Harrison CA et al. | Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. | 2007 | Br. J. Pharmacol. | pmid:17200674 |
| Zuany-Amorim C et al. | Characterization and pharmacological modulation of antigen-induced peritonitis in actively sensitized mice. | 1993 | Br. J. Pharmacol. | pmid:7694762 |
| Lampen A et al. | Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. | 1996 | Br. J. Pharmacol. | pmid:8732283 |
| Li J et al. | Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II. | 2005 | Br. J. Pharmacol. | pmid:15821752 |
| Macfarlane SR et al. | The role of intracellular Ca2+ in the regulation of proteinase-activated receptor-2 mediated nuclear factor kappa B signalling in keratinocytes. | 2005 | Br. J. Pharmacol. | pmid:15821758 |
| Oetjen E et al. | The immunosuppressive drugs cyclosporin A and tacrolimus inhibit membrane depolarization-induced CREB transcriptional activity at the coactivator level. | 2005 | Br. J. Pharmacol. | pmid:15711594 |